Moderna Withdraws Combined COVID-Flu Shot Application
Moderna’s decision to withdraw its application for a combined COVID-19 and influenza vaccine is a significant development, raising questions about the future of multi-vaccine approaches to infectious disease prevention. The company had previously reported promising results from a large-scale trial involving over 8,000 participants aged 50 and older. This trial demonstrated that the combination vaccine elicited significantly higher antibody levels against both COVID-19 and multiple influenza strains compared to receiving the individual vaccines separately. The increase in antibody levels was substantial, ranging from 20% to 40% higher, suggesting the potential for enhanced protection.
Despite these positive findings, the application was ultimately pulled.… Continue reading
Matt Underwood